Adjuvant palmitoylethanolamide therapy with risperidone improves negative symptoms in patients with schizophrenia: A randomized, double-blinded, placebo-controlled trial
Randomised controlled trialHumans
- Design
- Randomised controlled trial
- Subjects
- 60 patients with schizophrenia randomised. 50 completed, 25 in each group.
- Dose used in the study
- 600 mg twice a day, added to a stable dose of the antipsychotic risperidone. The comparison group took placebo with risperidone.
- Duration
- 8 weeks
- What was measured
- Negative symptoms on the PANSS scale as the main outcome, plus positive symptoms, depressive symptoms and movement side effects
What the authors reported
This randomized, double-blinded, placebo-controlled trial found:
- Negative symptoms improved more in the palmitoylethanolamide group (p = 0.012).
- Positive symptoms and depressive symptoms did not differ between the groups.
- Adverse events and movement side effects did not differ.
Limits of this study
All patients also took risperidone, so the trial tested palmitoylethanolamide as an add-on. Ten of the 60 patients did not complete. The trial ran for 8 weeks. Limitations were not visible on the page checked. It was funded by a grant from Tehran University of Medical Sciences.
Source
PubMed 35917650 · doi:10.1016/j.psychres.2022.114737
Entry checked against the abstract on PubMed, and the abstract page at the publisher (ScienceDirect) on 2026-10-19. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.